Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001685 · ClinicalTrials.gov registry record · Phase 2
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT00001685: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001685 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 114 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001685, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
This is a study of a melanoma tumor antigen peptide vaccine. Peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be administered emulsified in Incomplete Freund's Adjuvant, (IFA) to HLA-A201 patients with melanoma. The study is designed to evaluate the potential therapeutic role, immunologic effects and toxicity of repeated doses of this peptide vaccine administered subcutaneously. Immune reactivity to the peptide epitope will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization.
Interventions
- BIOLOGICAL Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 1997-11 |
| Est. Completion | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001685
The ClinicalTrials.gov registry entry for NCT00001685 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase is the first listed.
NCT00001685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001685 about?
NCT00001685 is a clinical study titled "Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase". This is a study of a melanoma tumor antigen peptide vaccine. Peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be administered emulsified in Incomplete Freund's Adjuvant, (IFA) to HLA-A201 patients with melanoma. The study is design...
What is the current status of trial NCT00001685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 1997-11. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00001685?
The interventions under investigation include: Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001685?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.